# Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

> **NCT02030184** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- Neuroendocrine (NE) Tumors
- Large Cell Neuroendocrine (NE) Tumors

## Interventions

- **DRUG:** Rhenium Re 188-P2045

## Key facts

- **NCT ID:** NCT02030184
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06
- **Primary completion:** 2019-06
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI has left the study institution.
- **Last updated:** 2019-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030184, "Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02030184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*